More Clinical Articles

Clinical

Cancer Metabolism Study Identifies New Potential Drug Targets Against Tumours

Anonymous, (Apr 22, 2013)

Several cancer metabolic expression changes have been discovered through a US study analysing gene expression data sourced from 22 types of tumours.
Clinical

Sanofi Abandons Alzheimer's Research

Zuzanna Fimińska, (Apr 17, 2013)

“Science isn’t advanced enough to justify the costs to develop a [Alzheimer’s] drug,” says Sanofi CEO, Chris Viehbacher.
Clinical

$13.6 Billion Buyout of Life Tech by Thermo Fisher Creates Personalized Medicine Heavyweight

Lucy Brake, (Apr 16, 2013)

In one of the America’s biggest corporate takeovers this year, science service provider Thermo Fisher Scientific has brought out the scientific and laboratory equipment maker Life Technologies Corporation for US$13.6 billion.
Clinical

Human Genome Patent: The US Supreme Court Wary of Owning Human DNA

Zuzanna Fimińska, (Apr 16, 2013)

After hearing arguments in a case concerning patents on human genes held by Myriad Genetics, the justices drew analogies with chocolate-chip cookies, baseball bats and Amazonian medicinal plants to find a narrow way to rule on a case that may change the course of biomedical research.
Clinical

America’s Biopharma Industry Shows Continued Commitment to Research

Lucy Brake, (Apr 15, 2013)

America’s biopharmaceutical industry continues to invest significant amounts of time, effort and financial resources into research and development according to the latest report from the Pharmaceutical Research and Manufacturers of America (PhRMA).
Clinical

Current Diabetes Research is Less Focused on Prevention and Excludes Several Types of Patients

Anonymous, (Apr 10, 2013)

Diabetes research is more focused on advancing drug therapies than preventative measures and is likely to exclude older people and young children, a US study demonstrates.
Clinical

Orphan Drugs May be Left Out in the Cold

Louise Kelly, (Apr 9, 2013)

Achieving orphan status for medicine development has resulted in many breakthroughs by drug manufacturers that may not have otherwise been achieved. But with the related financial incentives for the pharmaceutical industry now apparently in danger, will innovation for rare disease treatment suffer?
Clinical

One-of-a-Kind Combo Drug Provides a New Alternative for BRCA-Deficient Cancer Patients

Anonymous, (Apr 9, 2013)

A unique drug combination has elicited ground-breaking anti-tumour effects in patients with incurable BRCA-deficient cancers.
Clinical

Roche Agrees to Release all Tamiflu Data

Ben Steele, (Apr 5, 2013)

After a long battle, Swiss drugmaker Roche Holding AG has agreed to release all of its Tamiflu trial data to the Cochrane Collaboration, a health research body.
Clinical

Is Obama’s New Project a No-BRAINer?

Louise Kelly, (Apr 4, 2013)

Modelled on the Human Genome Project, President Obama revealed the blueprint for the ambitious BRAIN initiative this week. The venture has been lauded by many groups advocating brain research but critics are raising questions of uncertain funding and scientific challenges.

Pages